ReiThera is an Italian-based Contract Development and Manufacturing Organization (CDMO) specializing in the development and GMP manufacturing of viral vectors for genetic vaccines and advanced therapies. The company boasts a state-of-the-art facility equipped with various bioreactor systems, including stirred-tank bioreactors ranging from 50L to 2000L, and fixed-bed bioreactors for cell growth. ReiThera's expertise encompasses a wide range of viral vector technologies, including Adeno-Associated Viruses (AAV), Lentivirus, Adenoviral vectors, Modified Vaccinia Ankara, and Herpes Simplex Vector. This comprehensive capability allows ReiThera to support the clinical translation of innovative therapies from preclinical stages to commercial production.

The company is at the forefront of gene delivery technology, which is pivotal in advancing personalized medicine. By leveraging their extensive knowledge in immunology and genomics, ReiThera aims to overcome the challenges associated with the manufacturing and commercialization of viral vector-based therapies. Their ongoing research focuses on optimizing viral vector engineering to enhance the efficacy of immunotherapeutic and gene therapy products. Through their commitment to high-quality process development and manufacturing, ReiThera is positioned to play a significant role in the evolution of modern medicine, particularly in the realm of individualized treatments.

Italy

ReiThera is a company devoted to developing and producing biopharmaceutical products based on gene delivery technologies doe advanced therapies, in order to prevent and treat several serious or life-threatening diseases.

ReiThera

Company Details